NUVB
Nuvation Bio Inc - Class A (NUVB)
Healthcare • NYSE • $6.46+6.95%
- Symbol
- NUVB
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.46
- Daily Change
- +6.95%
- Market Cap
- $1.94B
- Trailing P/E
- N/A
- Forward P/E
- -92.67
- 52W High
- $9.75
- 52W Low
- $1.81
- Analyst Target
- $12.33
- Dividend Yield
- N/A
- Beta
- 1.56
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Company websiteResearch NUVB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.